Global Anti-Hypertensive Drugs Industry

  • February 2010
  • -
  • Global Industry Analysts

This report analyzes the worldwide markets for Anti-Hypertensive Drugs in US$ Million. The report provides separate comprehensive analytics for US, Europe and Rest of World. Annual forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 145 companies including many key and niche players worldwide such as AstraZeneca PLC, AstraZeneca PLC, Biovail Corp, Biovail Corp, Biovail Corp, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Forest Laboratories, Inc., Forest Laboratories, Inc., Merck & Co., Inc., Mylan, Inc., Novartis AG,. Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi-aventis, Solvay Pharmaceuticals SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, and The Medicines Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table Of Contents


ANTI-HYPERTENSIVE DRUGS MCP-6021
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-3
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. MARKET AT A GLANCE II-1
Introduction II-1
Hypertension - Prevalence II-1
Market Overview II-1
Current and Future Analysis II-2
ARBs Lead the World Anti-hypertension Drugs Market II-2
Lack of RandD Innovation, Genericization Characterize the Global
Anti-Hypertensive Drugs Market II-3

2. HYPERTENSION: Definition, Concerns, Consequences,
Categorization, Diagnosis, Treatment, Side Effects, and Leading
Drugs II-4
Definition II-4
Blood Pressure II-4
High Blood Pressure II-4
Concerns II-4
Consequences II-5
Hypertension and Diabetic Population II-5
Categorization II-5
Primary and Secondary Hypertension II-5
Acute Hypertension II-5
Diagnosis II-6
Treatment II-6
Lifestyle Modifications II-6
Avoiding Nicotine Products II-6
Avoiding Alcohol II-6
Avoiding Processed Foods II-6
Restricting Sodium II-7
Reducing Weight II-7
Adopting Biofeedback / Relaxation Techniques II-7
Anti-Hypertensive Drugs II-7
Beta Blockers II-7
Types of Beta-blockers II-8
Calcium Channel Blockers II-8
Types of Calcium Channel Blockers II-8
Angiotensin II Receptor Blockers II-8
Types of Angiotensin II Receptor Blockers II-9
ACE Inhibitors II-9
Types of ACE Inhibitors II-9
Diuretics II-10
Types of Diuretics II-10
Other Anti-hypertensive Drugs II-11
Renin Inhibitors II-11
Vasodilators II-11
Types of Vasodilators and Brand Names II-11
Alpha Blockers II-11
Mixed Blockers II-11
Adrenergic Receptor Agonist II-12
Aldosterone Receptor Antagonists II-12
Central Alpha Agonists II-12
Side Effects II-12
Side Effects by Drug Class II-12
Thiazide Diuretics II-12
Beta-blockers II-13
ACE Inhibitors II-13
Peripheral Vasodilators II-13
Side Effects by Drug Name II-13
Side Effects Profile of Select Anti-hypertensive Drugs II-13
Select Leading Anti-hypertensive Drugs: A Review II-15
Benicar/Olmetec II-15
Cleviprex II-15
Cozaar II-15
Diovan/Diovan HCT II-15
Exforge II-16
Norvasc II-16
Tekturna/Rasilez II-16
Tekturna HCT II-16

3. RESEARCH and DEVELOPMENT II-18
Takeda’s TAK-536 Reaches Phase III Clinical Trials in Japan II-18
China Pharma Commences Clinical Trials for Candesartan Generic II-18
Taipei Medical University Reveals Results of New Blood
Pressure Study II-18
Researchers Identify New Genes Affecting Blood Pressure II-18
Italian Study Demonstrates Benefits of Investigational
Amlodipine and Telmisartan Combination Treatment in Blood
Pressure Patients Exposed to Risk of Cardiovascular Events II-19
Gilead Sciences Announces Phase III Darusentan Data II-19
Gilead Sciences Commences Phase II Trial of Cicletanine II-20
New Clinical Data Demonstrates Effectiveness of Rasilez/
Tekturna in Obese Patients with Hypertension in Comparison to
Monotherapy with Diuretic Hydrochlorothiazide II-20
New Study Demonstrates Effectiveness of Exforge® in
Controlling High Blood Pressure in "difficult-to-treat"
Patients than Amlodipine Alone II-20
New Analyses Demonstrates Use of Cleviprex for Controlling
Perioperative Hypertension to Lower the Risk of Heart Attack
and Mortality Following Cardiac Surgery II-20
Surface Logix Announces Encouraging Phase IIa Results of SLx-2101 II-21
Observational Study Demonstrates Telmisartan to Provide
Powerful Blood Pressure Control for Complete 24-hours,
Including the Risky Hours of Early Morning II-21
New Study Demonstrates Tekturna® When Combined with Diovan® to
Have Additional Blood Pressure Lowering Effect II-22
Protherics Develops High Blood Pressure Vaccine II-22

4. PRODUCT INTRODUCTIONS II-23
Takeda Introduces ECARD for Hypertension Treatment II-23
Amneal Pharmaceuticals Introduces Benazepril HCI II-23
Ranbaxy Laboratories to Introduce Daiichi Sankyo's Olvance in
India II-23
Gemini Pharmaceuticals Launches Anti-hypertensive Medicine,
Micardis II-23
Shionogi Introduces Fluitran® 1mg II-24
Helvepharm Launches New Anti-hypertensive Drug II-24
Ranbaxy Laboratories Introduces Amlodipine II-24
Nicholas Piramal Launches Hypertension Management Device II-24
GlaxoSmithKline Introduces Ambrisentan II-24
Novartis Introduces Aliskiren II-24
Dainippon Introduces Avapro for Hypertension Treatment II-25
Shionogi Introduces Irbetan for Hypertension Treatment II-25
Pfizer Japan Introduces Sildenafil II-25
Surgipharm Launches Diovan and Co-diovan II-25
King Pharmaceuticals Introduces Altace Tablets II-25
Encysive Pharmaceuticals Introduces Thelin Tablets II-25
Dr Reddy's Laboratories Introduces Atocor-R II-26
Wockhardt to Introduce Amlodipine Tablets II-26
GlaxoSmithKline Launches Coreg CR Extended-Release Capsules II-26
Toray and Astellas Introduce Careload LA Tablets II-26
Encysive Introduces Sitaxentan Encysive II-26
GlaxoSmithKline Introduces Carzec II-27
Encysive Pharmaceuticals Introduces Thelin II-27
Ranbaxy Laboratories Introduces Generic Drug Verapamil II-27
Actavis Group Introduces NIFEdipine (XR) Tablets II-27
Apotex Introduces Norvasc Generic II-27
Novartis Introduces Aliskiren II-27
Encysive Introduces Sitaxentan II-28
Pfizer to Release the Generic Version of Norvasc II-28
Mylan Introduces Generic Blood Pressure Medicines II-28

5. RECENT INDUSTRY ACTIVITY II-29
Sanofi-Aventis Takes Over Helvepharm II-29
ARCA Biopharma Merges with Nuvelo II-29
Astellas and Nippon Receive Approval for Micombi®
Antihypertensive Drug II-29
The Medicines Co Announces EU Acceptance of MAA for Cleviprex II-29
Actelion and GeneraMedix Sign Definitive Agreement II-30
AtCor Medical Enters into Contract with Pharmaceutical Company II-30
Ranbaxy Receives FDA Approval for Anti-hypertensive Drug II-30
Sun Pharmaceuticals Receives Approval for Generic Version of
Accupril II-30
Sucampo Pharma Americas Wins Rights to Rescula II-30
Novartis Obtains Approval from Japanese Health Ministry II-31
Novartis Obtains FDA Approval for Exforge HCT II-31
Novartis Obtains Approval for Four New Medicines II-32
Aveva Drug Delivery Obtains Approval for Clonidine TDS II-32
Ranbaxy Receives Approval to Market Anti-Hypertension Drug II-32
Actelion Receives FDA Approval for New Ventavis Formulation II-32
Sinobiopharma Receives Chinese Approval for Perindopril II-32
Pfizer Acquires Encysive Pharmaceuticals II-33
GlaxoSmithKline Acquires Bristol Myers Squibb’s Egyptian Business II-33
Gilead Sciences Acquires Navitas’ Cicletanine Business Assets II-33
Shionogi Acquires Sciele Pharma II-34
Recordati Acquires Yeni Ilac II-34
Kyowa Hakko Merges with Kirin Pharma II-34
Belupo and Farmavita Announce Merger II-35
Daiichi Sankyo India and GlaxoSmithKline Sign Co-Promotion Deal II-35
Sciele Pharma and Addrenex Pharmaceuticals Sign Exclusive
Agreement II-35
Merck Serono Signs Distribution Agreement with Bristol-Myers
Squibb II-35
Forest Laboratories Holdings Amends Agreement with Mylan II-36
Speedel Secures FDA Approval for Tekturna HCT II-36
Lupin Receives FDA Approval for Generic Ramipril Capsules II-36
Daiichi Sankyo Submits Application for Anti-hypertensive Drug
Approval II-36
Mylan Receives FDA Approval for Nisoldipine Extended-Release II-37
Glenmark Wins FDA Approval for Trandolapril II-37
Novartis Obtains FDA Approval for Tekturna HCT II-37
Mylan Receives Tentative Approval for Generic Version of
Benicar HCT II-37
Novartis Secures Swissmedic Approval for Rasilez HCT II-37
Kyowa Secures Japanese Approval for Amlodipine Generic II-37
Aurobindo Pharma Obtains FDA Approval II-38
Actelion Receives EU Approval for Tracleer II-38
The Medicines Company Wins FDA Approval for Cleviprex II-38
Indian Pharmaceuticals Wins Approval for Propranolol
Hydrochloride Tablets II-38
Aurobindo Pharma Secures FDA Approval for Lotensin Generic II-38
Zydus Cadila Obtains FDA Approval for Marketing of Benazepril II-38
Mylan Wins FDA Approval for Mavik’s Generic II-39
Kampala Pharma to Commence Production of High Blood Pressure
Drugs II-39
Merck Extends Licensing Agreement with AstraZeneca II-39
Helpson Receives China FDA Approval to Market Bumetanide Generic II-39
Sciele Pharma Obtains FDA Approval II-39
DAIICHI SANKYO ILAÇ Acquires Anti-hypertensive Drug, Concor II-39
Novartis’ Rasilez HCT Receives European Committee Recommendation II-40
Pfizer Wins Patent Protection Lawsuit for Norvasc in Canada II-40
Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion
Agreement II-40
Novartis Wins Canadian Approval for Rasilez II-40
Hi-Tech Pharmacal Receives ANDA Approval from FDA II-40
Dr. Reddy's Receives FDA Approval for Trandolapril II-41
Quantum Genomics and PCAS Pharma Sign Strategic Agreement II-41
GeneraMedix Wins Approval from FDA for Epoprostenol II-41
Pharmaceutical Holdings Changes Name to URL Pharma II-41
Zydus Cadila Obtains Approval from U.S. FDA for Ramipril Capsules II-42
Zydus Cadila Obtains Approval from U.S. FDA for Four Drugs II-42
KV Pharmaceutical Obtains FDA Approval for Toprol-XL Generic II-42
Ranbaxy Pharmaceuticals and AstraZeneca Sign Agreements II-42
Recordati Completes Mutual Recognition with 28 European Nations II-43
Recordati Obtains Australian Approval for Zan-Extra® II-43
Santen Pharmaceutical Obtains Approval for TAPROS II-43
Santen Obtains Marketing Authorization for TAFLOTAN II-43
Boehringer Ingelheim Wins EU Commission Approval for
MicardisPlus® 80/25 II-44
Daiichi Sankyo Europe Obtains Marketing Approval of SEVIKAR® II-44
Daiichi Sankyo Establishes Subsidiary in Ireland II-44
GlaxoSmithKline Wins EC Marketing Approval for Volibris II-44
NicOx Enters into Alliance with Royal DSM II-45
NicOx Enters into Alliance with Archimica II-45
NicOx Enters into Alliance with Capsugel II-45
Novartis Obtains FDA Approval for Exforge and Diovan HCT II-45
Actelion and Merck Initiate Phase II Program Dosing, Reach
Fourth Milestone II-46
Jupiter Bioscience Acquires Drug Technology II-46
Recordati- Berlin Chemie Expand Licensing Agreement II-46
Meda and Recordati Enter into Agreement for Zaneril® II-46
Glenmark Wins FDA Approval for Coreg II-47
Novartis Secures FDA Approval for Exforge II-47
Caraco Receives ANDA Approval for Norvasc Generic II-47
Mylan and Forest Labs Win FDA Approval to Market Bystolic II-47
Daiichi Sankyo Secures FDA Approval for Azor II-47
Teva Bags Approval to Market Accupril Generic II-48
Meda and Recordati Sign Long-Term Agreement II-48
Ranbaxy Bags Approval to Produce and Market Amlodipine Besylate II-48
Caraco Receives FDA Approval for Atenolol Tablets II-48
Sciele Pharma and Addrenex Enter into Agreement II-49
Novartis Wins Swissmedic Approval for Tekturna II-49
Lupin Bags Approval to Market Prinivil’s Generic Version II-49
Aurobindo Pharma Receives FDA Approval for Accuretic’s
Generic Version II-49
Gilead Sciences Wins FDA Approval for Letairis II-49
Guangdong Luote Signs Agreement with Nippon Chemiphar II-50
Wockhardt Wins FDA Approval to Market Lisinopril II-50
Kaken to Commence Marketing Procylin for Pulmonary
Hypertension Treatment II-50
Encysive Pharma Wins Australian Approval for THELIN® II-50
Ranbaxy Wins Approval to Market Atenolol II-51
Novartis Secures EC Approval for Exforge II-51
Ranbaxy Receives Health Canada Approval for Lisinopril Tablets II-51
Ranbaxy Receives Tentative Approval for Valsartan Tablets II-51
Bristol-Myers and sanofi-aventis Obtain FDA Approval for AVALIDE II-52
Par Pharmaceutical Receives FDA Approval for Propranolol HCl ER II-52
Ranbaxy Receives Approval from FDA for Coreg Generic II-52
KV Pharmaceuticals Obtains FDA Approval for Toprol-XL Generic II-53
Mylan Wins Approval for Propranolol Hydrochloride ER Capsules II-53
Novartis Wins EU Approval for Rasilez II-53
Actavis Group Secures FDA Approval for Carvedilol Tablets II-53
Par Pharmaceuticals Ships ER Metoprolol Succinate Tablets II-53
Biovail Reaches Settlement Agreement with Watson Pharmaceuticals II-54
Lexicon Genetics Announces Name Change II-54

6. FOCUS ON SELECT MAJOR PLAYERS II-55
AstraZeneca PLC (UK) II-55
Bayer AG (Germany) II-55
Biovail Corp. (Canada) II-56
Boehringer Ingelheim GmbH (Germany) II-56
Bristol-Myers Squibb Company (USA) II-56
Daiichi Sankyo Company, Limited (Japan) II-57
Dr. Reddy's Laboratories Ltd. (India) II-57
Forest Laboratories, Inc. (USA) II-57
GlaxoSmithKline PLC (UK) II-58
Merck and Co., Inc. (USA) II-58
Mylan, Inc. (USA) II-59
Novartis AG (Switzerland) II-59
Pfizer, Inc. (USA) II-60
Ranbaxy Laboratories Limited (India) II-60
Sanofi-aventis (France) II-61
Solvay Pharmaceuticals SA (Belgium) II-61
Takeda Pharmaceutical Company Limited (Japan) II-61
Teva Pharmaceutical Industries Limited (Israel) II-62
The Medicines Company (USA) II-62

7. GLOBAL MARKET PERSPECTIVE II-64
Table 1: World Recent Past, Current and Future Analysis for
Anti-hypertensive Drugs by Geographic Region - US, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) II-64

Table 2: World Historic Review Analysis for Anti-hypertensive
Drugs by Geographic Region - US, Europe and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) II-65

Table 3: World 15-Year Perspective for Anti-hypertensive Drugs
by Geographic Region - Percentage Breakdown of Dollar Sales
for the US, Europe and Rest of World Markets for 2003, 2009 and
2015 (includes corresponding Graph/Chart) II-66


III. MARKET

1. UNITED STATES III-1
A.Market Analysis III-1
Hypertension - Prevalence III-1
Table 4: Hypertension Prevalence Among Adults in the US -
Percentage Share Breakdown by Age Group: 2005-2006 (includes
corresponding Graph/Chart) III-1

Table 5: Hypertension Prevalence Among Adults in the US -
Percentage Share Breakdown by Gender: 2005-2006 III-2

Table 6: Hypertension Prevalence Among Adults in the US -
Percentage Share Breakdown by Race/Ethnicity: 2005-2006
(includes corresponding Graph/Chart) III-2

Table 7: Hypertension Treatment Among Hypertensive Adults
in the US - Percentage Share Breakdown by Gender and Age
Group: 2005-2006 (includes corresponding Graph/Chart) III-2

Table 8: Hypertension Treatment Among Hypertensive Adults
in the US - Percentage Share Breakdown by Race/Ethnicity:
2005-2006 (includes corresponding Graph/Chart) III-3

Table 9: Outpatient Department Visit with Hypertension as
Co-morbid Chronic Condition in the US - Percentage Share
Breakdown by Age Group: 2006 (includes corresponding
Graph/Chart) III-3

Table 10: Outpatient Department Visits with Hypertension as
Co-morbid Chronic Condition in the US - Percentage Share
Breakdown by Gender: 2006 III-4
Market Overview III-4
Table 11: US Anti-hypertensive Drugs Market - Sales and
Percentage Share Breakdown by Leading Drugs in US$ Million
Between October 2007 and October 2008 (includes
corresponding Graph/Chart) III-4

Table 12: US Anti-hypertensive Drugs Market - Percentage
Share Breakdown of Leading Class of Drug Based on Total
Prescriptions for 2007 (includes corresponding Graph/Chart) III-5

Table 13: US Anti-hypertensive Drugs Market - Percentage
Share Breakdown of ACE Inhibitors Based on Total
Prescriptions for 2007 (includes corresponding Graph/Chart) III-5

Table 14: US Anti-hypertensive Drugs Market - Percentage
Share Breakdown of Angiotension Receptor Blockers (ARBs)
Based on Total Prescriptions for 2007 (includes
corresponding Graph/Chart) III-6
New Patient Therapy Starts to Witness Slowdown III-6
Table 15: US Anti-hypertensive Drugs Market - Percentage
Share Breakdown of Angiotensin II Receptor Blockers by New
Prescriptions for 2006, 2007 and 2008 (includes
corresponding Graph/Chart) III-6

Table 16: US Anti-hypertensive Drugs Market - Percentage
Share Breakdown of ACE Inhibitors by New Prescriptions for
2006, 2007 and 2008 (includes corresponding Graph/Chart) III-7

Table 17: US Anti-hypertensive Drugs Market - Percentage
Share Breakdown of Calcium Channel Blockers by New
Prescriptions for 2006, 2007 and 2008 (includes
corresponding Graph/Chart) III-8
African Americans At Major Health Risk Due to Hypertension III-8
Research and Development III-9
Product Launches III-10
Strategic Corporate Developments III-12
Select Players III-25
B.Market Analytics III-28
Table 18: US Recent Past, Current and Future Analysis for
Anti-hypertensive Drugs - Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-28

Table 19: US Historic Review Analysis for Anti-hypertensive
Drugs - Annual Sales Figures in US$ Million for Years 2001
through 2006 (includes corresponding Graph/Chart) III-28

2. EUROPE III-29
A.Market Analysis III-29
Hypertension - Prevalence III-29
Non-Invasive Blood Pressure Monitoring on Growth Trajectory III-29
Regional Markets at a Glance III-29
United Kingdom III-29
Hypertension - Prevalence III-29
Hypertension Treatment - Monotherapy and Combination
Therapies III-30
Denmark III-30
Cheaper Alternatives for Hypertension Treatment III-30
Norway III-30
New Branded Drugs Dominate Anti-hypertensive Drugs Market III-30
New Amendments to Medicines Reimbursement III-30
Proposed New Reimbursement Conditions in Norway III-31
Research and Development III-32
Product Launches III-34
Strategic Corporate Developments III-35
Select Players III-40
B.Market Analytics III-44
Table 20: European Recent Past, Current and Future Analysis
for Anti-hypertensive Drugs - Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-44

Table 21: European Historic Review Analysis for
Anti-hypertensive Drugs - Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-44

3. REST OF WORLD III-45
A.Market Analysis III-45
Canada III-45
Table 22: Canadian Anti-hypertensive Drugs Market - Total
Number of Prescriptions in Thousands for 1996 and 2006
(includes corresponding Graph/Chart) III-45
Japan III-46
Australia III-46
Australians to Shell Out More on Anti-Hypertensive Drugs III-46
China III-46
Hypertension - A Major Health Concern in China III-46
Anti-hypertensive Drugs Market III-47
Hypertension Outlook III-47
Competitive Landscape III-48
India III-48
Anti-Hypertensive Drugs Manufacturers III-48
Korea III-48
Anti-hypertensive Drugs Market III-48
Table 23: Korean Anti-hypertensive Drugs Market - Leading
Classes of Drugs by Value Sales in US$ Million for 2007,
2008, and 2009 (Q1) (includes corresponding Graph/Chart) III-49

Table 24: Korean Anti-hypertensive Drugs Market -
Percentage Share Breakdown of Leading Drugs by Outpatient
Prescription Value for 2007, 2008 and 2009 (H1) (includes
corresponding Graph/Chart) III-49
Anti-hypertension Drugs Market - Angiotensin Receptor Blockers III-50
Table 25: Korean Anti-hypertensive Drugs Market -
Percentage Share Breakdown of Leading Angiotension
Receptor Blockers by Prescription Value for 2008 and 2009
(Q1) (includes corresponding Graph/Chart) III-50
Anti-hypertension Drugs Market - Calcium Channel Blockers III-51
Table 26: Korean Anti-hypertensive Drugs Market -
Percentage Share Breakdown of Leading Calcium Channel
Blocker by Prescription Value for 2008 and 2009 (Q1)
(includes corresponding Graph/Chart) III-51
Anti-hypertension Drugs Market - Beta-blockers III-52
Table 27: Korean Anti-hypertensive Drugs Market -
Percentage Share Breakdown of Leading Beta- blockers for
2008 and 2009 (Q1) (includes corresponding Graph/Chart) III-52
Kenya III-53
Anti-hypertensive Drugs Market III-53
Manufacturing Overview III-53
Generics Erode Share of Ethical Drugs III-53
Research and Development III-54
Product Launches III-55
Strategic Corporate Developments III-57
Select Players III-64
B.Market Analytics III-67
Table 28: Rest of World Recent Past, Current and Future
Analysis for Anti-hypertensive Drugs - Annual Sales Figures
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-67

Table 29: Rest of World Historic Review Analysis for
Anti-hypertensive Drugs - Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-67


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 145 (including Divisions/Subsidiaries - 176)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 31
Canada 4
Japan 15
Europe 51
France 7
Germany 6
The United Kingdom 8
Italy 3
Spain 3
Rest of Europe 24
Asia-Pacific (Excluding Japan) 65
Latin America 2
Africa 2
Middle East 6
------------------------------------------

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • Dec 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound ...

Global Pediatric Drugs and Vaccines Market

Global Pediatric Drugs and Vaccines Market

  • $ 4 950
  • Industry report
  • September 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.